| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.
|
J Clin Oncol
|
2006
|
5.78
|
|
2
|
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.
|
J Clin Oncol
|
2009
|
5.42
|
|
3
|
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.
|
Ann Surg
|
2005
|
4.86
|
|
4
|
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
4.68
|
|
5
|
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
|
J Clin Oncol
|
2008
|
4.37
|
|
6
|
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer.
|
J Clin Oncol
|
2009
|
2.52
|
|
7
|
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
|
J Clin Oncol
|
2009
|
2.52
|
|
8
|
High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome.
|
J Clin Oncol
|
2011
|
2.28
|
|
9
|
Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.
|
J Clin Oncol
|
2012
|
2.22
|
|
10
|
Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.
|
Cancer
|
2007
|
2.12
|
|
11
|
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy.
|
Cancer
|
2013
|
2.09
|
|
12
|
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
|
J Clin Oncol
|
2009
|
1.88
|
|
13
|
A novel platform for detection of CK+ and CK- CTCs.
|
Cancer Discov
|
2011
|
1.88
|
|
14
|
Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer.
|
Cancer
|
2007
|
1.86
|
|
15
|
Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.50
|
|
16
|
Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
|
J Clin Oncol
|
2008
|
1.45
|
|
17
|
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2009
|
1.43
|
|
18
|
Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience.
|
Cancer
|
2010
|
1.37
|
|
19
|
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.
|
J Clin Oncol
|
2010
|
1.36
|
|
20
|
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
|
Invest New Drugs
|
2011
|
1.33
|
|
21
|
Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
|
Int J Radiat Oncol Biol Phys
|
2004
|
1.31
|
|
22
|
Practical application of a calculator for conditional survival in colon cancer.
|
J Clin Oncol
|
2009
|
1.30
|
|
23
|
Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer.
|
Am J Clin Oncol
|
2006
|
1.29
|
|
24
|
Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome.
|
Cancer
|
2009
|
1.29
|
|
25
|
Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival.
|
J Gastrointest Surg
|
2007
|
1.25
|
|
26
|
Long-term survival and recurrence outcomes following surgery for distal rectal cancer.
|
Ann Surg Oncol
|
2010
|
1.24
|
|
27
|
Predictors and patterns of recurrence after definitive chemoradiation for anal cancer.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.23
|
|
28
|
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.21
|
|
29
|
GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes.
|
Carcinogenesis
|
2012
|
1.16
|
|
30
|
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.16
|
|
31
|
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.
|
J Clin Oncol
|
2014
|
1.14
|
|
32
|
Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005.
|
Am J Clin Oncol
|
2011
|
1.14
|
|
33
|
Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation.
|
Int J Radiat Oncol Biol Phys
|
2009
|
1.10
|
|
34
|
Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients.
|
Clin Cancer Res
|
2012
|
1.08
|
|
35
|
Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.
|
Ann Surg Oncol
|
2009
|
1.08
|
|
36
|
The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.
|
PLoS One
|
2013
|
1.08
|
|
37
|
Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade.
|
Ann Surg
|
2013
|
1.05
|
|
38
|
Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.
|
Cancer
|
2010
|
1.05
|
|
39
|
Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer.
|
Clin Cancer Res
|
2011
|
1.03
|
|
40
|
Cetuximab in the treatment of patients with colorectal cancer.
|
Expert Opin Biol Ther
|
2011
|
1.02
|
|
41
|
Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma.
|
Cancer
|
2011
|
1.02
|
|
42
|
Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation.
|
Dig Dis Sci
|
2009
|
1.00
|
|
43
|
The current landscape of locally advanced rectal cancer.
|
Nat Rev Clin Oncol
|
2011
|
0.99
|
|
44
|
Epidemiology, staging, and screening of head and neck cancer.
|
Cancer Treat Res
|
2003
|
0.99
|
|
45
|
Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI).
|
Cancer
|
2010
|
0.98
|
|
46
|
Metformin use and improved response to therapy in rectal cancer.
|
Cancer Med
|
2013
|
0.97
|
|
47
|
Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases.
|
Clin Colorectal Cancer
|
2008
|
0.96
|
|
48
|
A twenty-year experience with adenocarcinoma of the anal canal.
|
Dis Colon Rectum
|
2009
|
0.96
|
|
49
|
Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
|
Am J Clin Oncol
|
2014
|
0.95
|
|
50
|
Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007.
|
Cancer
|
2014
|
0.92
|
|
51
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
|
Clin Cancer Res
|
2004
|
0.92
|
|
52
|
Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.92
|
|
53
|
Long-term quality of life after radiotherapy for the treatment of anal cancer.
|
Cancer
|
2010
|
0.90
|
|
54
|
The promise of mTOR inhibitors in the treatment of colorectal cancer.
|
Expert Opin Investig Drugs
|
2012
|
0.89
|
|
55
|
A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.
|
Cancer
|
2010
|
0.89
|
|
56
|
Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas.
|
Oncologist
|
2013
|
0.89
|
|
57
|
Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.88
|
|
58
|
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
|
Expert Opin Drug Metab Toxicol
|
2012
|
0.88
|
|
59
|
Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
|
J Surg Oncol
|
2013
|
0.87
|
|
60
|
Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
|
Support Care Cancer
|
2013
|
0.87
|
|
61
|
Prognostic factors for squamous cell cancer of the anal canal.
|
Gastrointest Cancer Res
|
2008
|
0.86
|
|
62
|
Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness.
|
Clin Colorectal Cancer
|
2008
|
0.86
|
|
63
|
Mode effects in the center for epidemiologic studies depression (CES-D) scale: personal digital assistant vs. paper and pencil administration.
|
Qual Life Res
|
2007
|
0.86
|
|
64
|
Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer.
|
Gastrointest Cancer Res
|
2007
|
0.85
|
|
65
|
Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy.
|
Clin Cancer Res
|
2012
|
0.85
|
|
66
|
Multidetector computed tomography follow-up of hypoattenuating small liver lesions in patients with rectal cancer.
|
Am J Clin Oncol
|
2011
|
0.85
|
|
67
|
Interactions between cigarette smoking and selected polymorphisms in xenobiotic metabolizing enzymes in risk for colorectal cancer: A case-only analysis.
|
Mol Carcinog
|
2010
|
0.83
|
|
68
|
Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma.
|
Cancer
|
2012
|
0.82
|
|
69
|
Cetuximab in refractory squamous cell carcinoma of the anal canal.
|
J Gastrointest Cancer
|
2014
|
0.81
|
|
70
|
Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab.
|
J Vasc Interv Radiol
|
2007
|
0.81
|
|
71
|
Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum.
|
Am J Clin Oncol
|
2017
|
0.80
|
|
72
|
Emerging drugs for colorectal cancer.
|
Expert Opin Emerg Drugs
|
2008
|
0.80
|
|
73
|
Fatal diffuse alveolar damage associated with oxaliplatin administration.
|
Clin Colorectal Cancer
|
2011
|
0.80
|
|
74
|
Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary.
|
Clin Colorectal Cancer
|
2012
|
0.78
|
|
75
|
Commentary: practice patterns and potential impact on quality measures for a practicing physician.
|
J Oncol Pract
|
2009
|
0.78
|
|
76
|
The current state of targeted agents in rectal cancer.
|
Int J Surg Oncol
|
2012
|
0.78
|
|
77
|
Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.
|
Oncology
|
2016
|
0.77
|
|
78
|
Optimal treatment strategies for anal cancer.
|
Curr Treat Options Oncol
|
2014
|
0.77
|
|
79
|
Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma.
|
Carcinogenesis
|
2012
|
0.77
|
|
80
|
Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy.
|
Am J Clin Oncol
|
2016
|
0.77
|
|
81
|
Epidermal growth factor receptor inhibition in metastatic anal cancer.
|
Anticancer Drugs
|
2016
|
0.77
|
|
82
|
Genomic analysis and selected molecular pathways in rare cancers.
|
Phys Biol
|
2012
|
0.76
|
|
83
|
Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver.
|
Clin Colorectal Cancer
|
2006
|
0.76
|
|
84
|
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.
|
JCI Insight
|
2017
|
0.75
|
|
85
|
The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
|
Clin Adv Hematol Oncol
|
2007
|
0.75
|
|
86
|
Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases.
|
Clin Colorectal Cancer
|
2008
|
0.75
|
|
87
|
Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation.
|
Am J Clin Oncol
|
2016
|
0.75
|
|
88
|
Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series.
|
Acta Oncol
|
2012
|
0.75
|
|
89
|
Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
|
Ann Surg
|
2017
|
0.75
|
|
90
|
Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer.
|
Cancer
|
2006
|
0.75
|